T3 Pharma Nears The Clinic With Live Bacteria To Treat Cancer
Five-Year-Old Swiss Biotech Raises CHF25m To Pursue Novel Approach
Using live bacteria modified to deliver specific proteins to treat cancer is to be explored by the Swiss start-up, T3 Pharmaceuticals, which has garnered a large third round of funding from a European corporate VC, institutional and private investors, to advance its lead candidate into clinical trials.
You may also be interested in...
The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.